EA201390082A1 - Способ получения рекомбинантного adamts13 в культуре клеток - Google Patents

Способ получения рекомбинантного adamts13 в культуре клеток

Info

Publication number
EA201390082A1
EA201390082A1 EA201390082A EA201390082A EA201390082A1 EA 201390082 A1 EA201390082 A1 EA 201390082A1 EA 201390082 A EA201390082 A EA 201390082A EA 201390082 A EA201390082 A EA 201390082A EA 201390082 A1 EA201390082 A1 EA 201390082A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell culture
specific activity
present
high specific
culture conditions
Prior art date
Application number
EA201390082A
Other languages
English (en)
Other versions
EA029503B1 (ru
Inventor
Леопольд Грилльбергер
Манфред Райтер
Даниель Фляйшандерль
Грегор Брамбергер
Original Assignee
Бакстер Интернэшнл Инк.
Бакстер Хелткэр С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201390082(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бакстер Интернэшнл Инк., Бакстер Хелткэр С.А. filed Critical Бакстер Интернэшнл Инк.
Publication of EA201390082A1 publication Critical patent/EA201390082A1/ru
Publication of EA029503B1 publication Critical patent/EA029503B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится, среди прочих аспектов, к условиям культивирования клеток для получения высокомолекулярного vWF, в частности WF, состоящего из большого количества мультимеров, с высокой удельной активностью и ADAMTS13 с высокой удельной активностью. Условия культивирования клеток согласно настоящему изобретению могут включать, например, среду для клеточной культуры с повышенной концентрацией меди и/или супернатант культуры клеток с низкой концентрацией аммония (NH). Настоящее изобретение также обеспечивает способы культивирования клеток в условиях клеточной культуры для экспрессии высокомолекулярных vWF и rA13, обладающих высокой удельной активностью.
EA201390082A 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток EA029503B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36263510P 2010-07-08 2010-07-08
PCT/US2011/043459 WO2012006594A1 (en) 2010-07-08 2011-07-08 Method of producing recombinant adamts13 in cell culture

Publications (2)

Publication Number Publication Date
EA201390082A1 true EA201390082A1 (ru) 2013-06-28
EA029503B1 EA029503B1 (ru) 2018-04-30

Family

ID=44514323

Family Applications (5)

Application Number Title Priority Date Filing Date
EA202090067A EA202090067A3 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток
EA201390080A EA035066B1 (ru) 2010-07-08 2011-07-08 СПОСОБ ПОЛУЧЕНИЯ КУЛЬТУРАЛЬНОЙ ЖИДКОСТИ КЛЕТОК МЛЕКОПИТАЮЩЕГО, СОДЕРЖАЩЕЙ ВЫСОКОМОЛЕКУЛЯРНЫЙ РЕКОМБИНАНТНЫЙ ФАКТОР ФОН ВИЛЛЕБРАНДА (rVWF)
EA202090220A EA202090220A3 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного высокомолекулярного vwf в культуре клеток
EA201792340A EA035147B1 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток
EA201390082A EA029503B1 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EA202090067A EA202090067A3 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток
EA201390080A EA035066B1 (ru) 2010-07-08 2011-07-08 СПОСОБ ПОЛУЧЕНИЯ КУЛЬТУРАЛЬНОЙ ЖИДКОСТИ КЛЕТОК МЛЕКОПИТАЮЩЕГО, СОДЕРЖАЩЕЙ ВЫСОКОМОЛЕКУЛЯРНЫЙ РЕКОМБИНАНТНЫЙ ФАКТОР ФОН ВИЛЛЕБРАНДА (rVWF)
EA202090220A EA202090220A3 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного высокомолекулярного vwf в культуре клеток
EA201792340A EA035147B1 (ru) 2010-07-08 2011-07-08 Способ получения рекомбинантного adamts13 в культуре клеток

Country Status (25)

Country Link
US (8) US9458222B2 (ru)
EP (6) EP3626736A1 (ru)
JP (3) JP5953502B2 (ru)
KR (4) KR102007773B1 (ru)
CN (4) CN108060154A (ru)
AU (6) AU2011274470B2 (ru)
BR (2) BR112013000512A2 (ru)
CA (2) CA2804275A1 (ru)
CO (2) CO6690745A2 (ru)
DK (3) DK2591094T3 (ru)
EA (5) EA202090067A3 (ru)
ES (4) ES2761692T5 (ru)
FI (1) FI3064508T4 (ru)
HR (3) HRP20192089T4 (ru)
HU (3) HUE11738351T2 (ru)
IL (5) IL286298B (ru)
MX (3) MX339632B (ru)
NZ (2) NZ605404A (ru)
PL (4) PL3392271T3 (ru)
PT (3) PT3064508T (ru)
SG (3) SG186936A1 (ru)
SI (3) SI2591094T1 (ru)
TR (1) TR201815211T4 (ru)
TW (4) TWI670073B (ru)
WO (2) WO2012006594A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2685503T3 (es) 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
TWI670073B (zh) 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
WO2012171031A1 (en) * 2011-06-10 2012-12-13 Baxter International Inc. Treatment of coagulation disease by administration of recombinant vwf
US9030963B2 (en) * 2012-12-03 2015-05-12 Honeywell International Inc. Analyzing a network topology
UY35343A (es) * 2013-02-26 2014-09-30 Bayer Healthcare Llc Formulaciones y procedimientos para la producción de proteína recombinante aumentada
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
ES2924393T3 (es) * 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
WO2015188224A1 (en) * 2014-06-13 2015-12-17 Csl Limited Improved production of recombinant von willebrand factor in a bioreactor
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
WO2016126339A1 (en) * 2015-02-05 2016-08-11 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
CN106957815B (zh) * 2017-03-16 2021-05-07 杨涛 一种用于人类多潜能干细胞的无血清培养基的配方
PT3648788T (pt) 2017-07-07 2024-08-23 Takeda Pharmaceuticals Co Tratamento de hemorragia gastrointestinal em pacientes com doença de von willebrand grave por administração de fvw recombinante
RU2766118C2 (ru) 2017-07-07 2022-02-08 Такеда Фармасьютикал Компани Лимитед Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв
EP3768697A1 (en) 2018-03-21 2021-01-27 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
CN113645993A (zh) 2019-02-01 2021-11-12 武田药品工业株式会社 使用重组VWF(rVWF)进行预防性治疗的方法
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10961500B1 (en) * 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
EP4028046B1 (en) 2019-09-11 2024-02-14 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
JP2023514541A (ja) 2020-02-04 2023-04-06 武田薬品工業株式会社 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
NL8500961A (nl) 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
JP3649249B2 (ja) 1995-02-23 2005-05-18 クエスト・インターナショナル・サービシーズ・ビー・ブイ 組織および細胞培養用ペプチド
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
DE69738806D1 (de) 1996-10-10 2008-08-14 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
US6156570A (en) * 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CA2466881A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
KR100982922B1 (ko) 2002-01-17 2010-09-20 론자 바이올로직스 피엘씨 단백질을 생산할 수 있으며 무글루타민 배지에서 성장할 수있는 글루타민-요구성 인간세포
US20050084828A1 (en) 2003-10-21 2005-04-21 The University Of North Carolina At Chapel Hill Apparatus and method for braille instruction
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
RS51913B (en) * 2004-11-02 2012-02-29 Ares Trading S.A. Mammalian cell culture medium without serum content
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN101490239A (zh) * 2006-07-14 2009-07-22 帝斯曼知识产权资产管理有限公司 改进的细胞培养方法
SG174804A1 (ru) * 2006-09-13 2011-10-28 Abbott Lab
US7960869B2 (en) 2006-09-22 2011-06-14 Siemens Industry, Inc. Internal intelligence for remote operated relay
EP2114458B1 (en) * 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
AU2008223133A1 (en) * 2007-03-02 2008-09-12 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
DE102007046611A1 (de) * 2007-09-28 2009-04-02 Osram Opto Semiconductors Gmbh Lichtquelle mit Konversionselement und Lichtwellenleiter, Verfahren zur Herstellung der Lichtquelle und deren Verwendung
US9359629B2 (en) * 2007-12-27 2016-06-07 Baxalta Incorporated Cell culture processes
PL2240578T3 (pl) 2007-12-31 2019-09-30 Baxalta GmbH Rekombinowana furyna zasadniczo wolna od białka zwierzęcego i sposoby jej wytwarzania
JP4458167B2 (ja) * 2008-01-11 2010-04-28 住友金属工業株式会社 熱間塑性加工用潤滑剤を用いる継目無管製造における外面潤滑方法
US20110086813A1 (en) 2008-03-19 2011-04-14 Gad Glaser Compounds for treating bacterial infections
SI2310523T1 (sl) * 2008-04-17 2015-10-30 Wyeth Llc Postopki za boljšo proizvodnjo kostnih morfogenetskih proteinov
US8486699B2 (en) 2008-05-23 2013-07-16 The United States Of America As Represented By The Secretary Of Agriculture Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
KR101574056B1 (ko) * 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
TWI670073B (zh) 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
TWI408228B (zh) 2010-10-29 2013-09-11 Univ Nat Chunghsing 用於生產一標的蛋白質的核酸建構物、重組型載體以及方法

Also Published As

Publication number Publication date
IL255327A0 (en) 2017-12-31
US20120035110A1 (en) 2012-02-09
ES2761692T5 (es) 2023-07-05
PT3064508T (pt) 2019-12-05
TR201815211T4 (tr) 2018-11-21
IL223929A (en) 2017-11-30
HRP20181657T1 (hr) 2019-03-08
JP5953502B2 (ja) 2016-07-20
HUE046443T2 (hu) 2020-03-30
DK2591094T3 (en) 2018-11-26
AU2011274470B2 (en) 2015-08-13
TW201204744A (en) 2012-02-01
FI3064508T4 (fi) 2023-04-25
EP2591094A1 (en) 2013-05-15
IL223930A (en) 2017-01-31
IL286298A (en) 2021-10-31
HUE038193T2 (hu) 2018-09-28
US9834591B2 (en) 2017-12-05
EA035147B1 (ru) 2020-05-06
KR102007773B1 (ko) 2019-08-06
EP3064508B2 (en) 2023-03-15
HRP20192089T4 (hr) 2023-04-28
WO2012006591A1 (en) 2012-01-12
TWI646972B (zh) 2019-01-11
US8852888B2 (en) 2014-10-07
SI2590998T1 (en) 2018-06-29
KR20130091329A (ko) 2013-08-16
CA2804275A1 (en) 2012-01-12
JP2016025873A (ja) 2016-02-12
TW201206953A (en) 2012-02-16
IL286298B (en) 2022-08-01
AU2018200206A1 (en) 2018-04-05
US10822394B2 (en) 2020-11-03
HRP20192089T1 (hr) 2020-03-20
PT2591094T (pt) 2018-11-20
US11780904B2 (en) 2023-10-10
US20120034674A1 (en) 2012-02-09
ES2875772T3 (es) 2021-11-11
KR102027991B1 (ko) 2019-10-02
AU2011274467B2 (en) 2015-01-15
KR20130091328A (ko) 2013-08-16
SG186935A1 (en) 2013-02-28
EP3064508A1 (en) 2016-09-07
TWI609890B (zh) 2018-01-01
TW201900207A (zh) 2019-01-01
MX2013000166A (es) 2013-06-05
US10100099B2 (en) 2018-10-16
SI3064508T1 (sl) 2019-12-31
AU2018200206B2 (en) 2020-05-28
EP3392271B8 (en) 2021-06-16
AU2015207811B2 (en) 2017-10-19
US20150018525A1 (en) 2015-01-15
JP2013533748A (ja) 2013-08-29
JP2013538046A (ja) 2013-10-10
CO6690745A2 (es) 2013-06-17
MX339632B (es) 2016-06-02
BR112013000515B1 (pt) 2021-11-03
US20170008948A1 (en) 2017-01-12
WO2012006594A1 (en) 2012-01-12
EP3909977A1 (en) 2021-11-17
NZ605404A (en) 2014-08-29
HRP20180136T1 (hr) 2018-04-06
IL273304B (en) 2021-09-30
PL3064508T3 (pl) 2020-02-28
EP3626736A1 (en) 2020-03-25
AU2020203565A1 (en) 2020-06-18
AU2011274470A1 (en) 2013-01-24
JP2017217004A (ja) 2017-12-14
BR112013000512A2 (pt) 2016-05-17
TWI617575B (zh) 2018-03-11
IL273304A (en) 2020-04-30
MX353409B (es) 2018-01-11
PL2591094T3 (pl) 2019-02-28
EA202090067A2 (ru) 2020-04-30
PL2590998T3 (pl) 2018-05-30
EP3392271A1 (en) 2018-10-24
EA201792340A2 (ru) 2018-02-28
US9409971B2 (en) 2016-08-09
KR101924120B1 (ko) 2018-11-30
ES2761692T3 (es) 2020-05-20
KR20180130587A (ko) 2018-12-07
CO6680636A2 (es) 2013-05-31
ES2664392T3 (es) 2018-04-19
AU2020203565B2 (en) 2021-09-30
EA035066B1 (ru) 2020-04-23
EA029503B1 (ru) 2018-04-30
JP6138683B2 (ja) 2017-05-31
EP2590998A1 (en) 2013-05-15
EP2591094B1 (en) 2018-09-05
DK3064508T3 (da) 2019-11-25
SG186936A1 (en) 2013-02-28
CN103097522A (zh) 2013-05-08
CN103097409A (zh) 2013-05-08
KR101894604B1 (ko) 2018-09-03
AU2015207811A1 (en) 2015-08-20
EP2590998B1 (en) 2017-11-15
EA202090067A3 (ru) 2020-07-31
CN107286235A (zh) 2017-10-24
EA202090220A2 (ru) 2020-05-31
PL3392271T3 (pl) 2021-11-15
IL255327B (en) 2020-04-30
NZ605403A (en) 2014-10-31
EA201792340A3 (ru) 2018-07-31
CN108060154A (zh) 2018-05-22
EA201390080A1 (ru) 2013-06-28
BR112013000515A2 (pt) 2016-05-17
EP3392271B1 (en) 2021-05-05
US20190085052A1 (en) 2019-03-21
AU2011274467A1 (en) 2013-01-24
PT2590998T (pt) 2018-02-13
DK2590998T3 (en) 2018-02-12
MX2013000165A (es) 2013-06-05
US9458222B2 (en) 2016-10-04
SI3064508T2 (sl) 2023-05-31
US20180044405A1 (en) 2018-02-15
TWI670073B (zh) 2019-09-01
ES2694518T3 (es) 2018-12-21
EA202090220A3 (ru) 2020-08-31
SI2591094T1 (sl) 2018-12-31
HUE11738351T2 (hu) 2019-03-28
US20150056657A1 (en) 2015-02-26
CA2805557A1 (en) 2012-01-12
AU2022200035A1 (en) 2022-01-20
DK3064508T4 (da) 2023-04-11
TW201637665A (zh) 2016-11-01
JP6284919B2 (ja) 2018-02-28
EP3064508B1 (en) 2019-08-28
SG10201809632XA (en) 2018-12-28
KR20180099922A (ko) 2018-09-05
PL3064508T5 (pl) 2024-04-08
US20210115110A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
EA201390082A1 (ru) Способ получения рекомбинантного adamts13 в культуре клеток
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
BR112013002811A2 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX365435B (es) Metodos de modificacion de celulas huesped.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
EA201270224A1 (ru) Среда для культивирования клеток для экспрессии белков adamts
MX2015017110A (es) Integracion dirigida.
NZ705745A (en) Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
EA201491526A1 (ru) Способ культивирования бычьих и свиных сперматогониальных стволовых клеток без использования клеток-фидеров
DE602005021379D1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
BR112016007727A8 (pt) célula hospedeira, e, método para produzir uma proteína n-glicosilada.
WO2011159684A3 (en) Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2010096588A3 (en) Cell culture media containing combinations of proteins
EA201270173A1 (ru) Получение полиовируса с высокими титрами для получения вакцины
BR112014031424A2 (pt) tratamento de células pluripotentes
BR112017027527A2 (pt) ?método para a produção de feromônios de mariposas em levedura
IN2015MN00436A (ru)
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
WO2013016724A3 (en) Decarboxylase proteins with high keto-isovalerate decarboxylase activity
BR112013027860A2 (pt) ácido nucleico isolado, planta ou célula vegetal, método para aumentar a capacidade do dreno, acelerar a remobilização e/ou a senescência e a secagem de grão em uma planta, método para aumentar a tolerância a seca na ausência de uma penalidade de produtividade sob condições sem seca, cassete de expressão e método para reduzir a expressão de zmme293 ou a atividade de zmme293 em uma planta
MY171544A (en) A cell with reduced ppgppase activity
AR087980A1 (es) Actividad de dnasa endogena para reducir el contenido de adn
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
MX350005B (es) Microorganismos fermentadores de pentosa.

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM